JOHNSON & JOHNSON is 439.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($573.71 B vs $1.31 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MLTX | JNJ |
|---|---|---|
| Market cap | $1.31 B | $573.71 B |
| US-listed rank | #2448 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$227.32M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 296 | 984 |
JOHNSON & JOHNSON is 439.1x more valuable than MoonLake Immunotherapeutics by market capitalization ($573.71 B vs $1.31 B).
Full pages: MoonLake Immunotherapeutics and JOHNSON & JOHNSON, or browse the full rankings.